Ken Griffin Bridge Bio Pharma, Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 332,325 shares of BBIO stock, worth $16.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
332,325
Previous 256,900
29.36%
Holding current value
$16.3 Million
Previous $8.88 Million
61.57%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding BBIO
# of Institutions
408Shares Held
188MCall Options Held
11.3MPut Options Held
2.2M-
Viking Global Investors LP18.6MShares$911 Million2.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.5MShares$809 Million0.01% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY13.3MShares$651 Million22.63% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$611 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X09.28MShares$455 Million0.21% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $7.28B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...